RxDoctor Payments Data

Srinidhi Jayadevappa Meera

Cardiovascular Disease · Seattle, WANPI 1073919627

Payments from drug & device makers

$6,059in general payments, 2019–2025

Across 15 payments — averaging $403.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bridgebio Pharma, Inc.$5K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$210
  • Medtronic$130
  • Johnson & Johnson$125
  • AstraZeneca$124
  • Boehringer Ingelheim$95
  • plus $45 from 3 others

What the payments were for

  • Speaking & faculty fees$4,20069%
  • Travel & lodging$88215%
  • Food & beverage$97716%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,059 in reported general payments places this provider in the 80th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$153,147
Medicare patients
1,138
Services billed
2,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis15$334,266
EliquisApixaban261$289,386
EntrestoSacubitril/Valsartan32$33,440
FarxigaDapagliflozin Propanediol38$31,820
Repatha SyringeEvolocumab31$24,793
JardianceEmpagliflozin27$20,817
XareltoRivaroxaban18$19,554
Praluent PenAlirocumab16$10,842
Metoprolol Succinate400$5,647
Flecainide Acetate25$2,829
Rosuvastatin Calcium163$2,733
Torsemide59$2,232
Ezetimibe73$1,953
Potassium Chloride53$1,905
Atorvastatin Calcium168$1,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$124$31,82038 claims
Boehringer IngelheimJardiance$95$20,81727 claims
Johnson & JohnsonXarelto$125$19,55418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →